The RD Biomed team has recently enjoyed a successful three-month trip to China connecting with our strategic partner for the region, Maxhealth.
Business Development Manager Mark Atherton and Andrew Woodcock, our QA/RA Manager, headed out to China to provide insight into reflux diagnostic device, Peptest – the first trip for the team since the Covid pandemic curbed international travel.
Peptest was officially approved by Chinese health authorities and launched in the country in 2019.
After spending the first month in quarantine, the RD Biomed team were then able to help with the training of Peptest for sales teams from different provinces of China.
All training took place at the Maxhealth site in Wuxi under the supervision of Maxhealth’s Director of Medical Marketing Department, Xuting Zhang.
Maxhealth is a leading platform for R&D (research and development), production and commercialisation of innovative medical technology in China.
Peptest detects pepsin — the stomach enzyme that indicates reflux — in a saliva sample. Developed by the late Professor Peter Dettmar and used in over 40 countries, it is available directly to patients as well as NHS and private clinics.
- CE-IVD certified
- ISO 13485 manufacture
- Validated in 1,033-patient UK study
- Used in NHS voice clinics
Recent Comments